Expansion of a US generic drug price-fixing lawsuit brought by 46 states and territories seems likely to continue even after the addition of 12 companies and two executives as defendants.
"Our ongoing investigation continues to uncover additional evidence, and we anticipate bringing more claims involving additional companies and drugs at...







